Globally, as of 9 August, 19 cases of polio due to wild poliovirus type 1 (WPV1) and 223 cases due to circulating vaccine derived poliovirus (cVDPV) have been reported this year. In 2022, the cVDPV cases have been reported in 15 countries, with 93% of the cases attributed to cVDPV type 2 (cVDPV2).
The third meeting of the International Health Regulations Emergency Committee, held from 2-7 November 2014, regarding the international spread of wild poliovirus, states that the situation still constitutes a Public Health Emergency of International Concern (PHEIC).
The conclusions of the expert discussions on 31 July 2014 confirmed that conditions for a Public Health Emergency of International Concern (PHEIC) continue to be met for wild poliovirus i.e. that the international spread of polio in 2014 continues to constitute an extraordinary event and a public health risk to other states for which a coordinated international response continues to be essential.
In response to the correspondence published in The Lancet, “Polio emergence in Syria and Israel endangers Europe”, ECDC replied clarifying the Centre’s recommendations to Member States.
The authors retrospectively analyzed hepatitis A virus (HAV) seroprevalence in travellers who had been born and lived at least 1 year in a developing country, wanted to travel to a hepatitis A endemic area, and consulted at the vaccination centre of the Institut Pasteur of Paris between September 1, 2008 and February 28, 2010. HAV seroprevalence was 82.4 % for a population of 646 immigrants for whom data were available
In July–November 2009, 26 European Union Member States, Norway and Iceland, participated in a survey seeking information on national tick-borne encephalitis (TBE) vaccination recommendations.